Drug Regulation Rosiglitazone: what went wrong?

[1] *AM DIAB ASS, FDA REV DAT 2 NEW DI

[2] CALABRESI M, 1916, TIME 0816

[3] Department of Health and Human Services, 2010, ADV COMM M NDA 21071

[4] The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study [J]. PLOS MEDICINE, 2009, 6 (09)

[5] *EUR MED AG, 2001, EPAR AV

[6] *EUR MED AG, AV PROC STEPS TAK SC

[7] Lessons from the glitazones: a story of drug development [J]. LANCET, 2001, 357 (9271) : 1870 - 1875

[8] Harris G., 2010, NY TIMES 0713

[9] Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial [J]. LANCET, 2009, 373 (9681) : 2125 - 2135

[10] Thiazolidinediones for type 2 diabetes - New agents reduce insulin resistance but need long term clinical trials [J]. BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7256): : 252 - 253

[1] *AM DIAB ASS, FDA REV DAT 2 NEW DI

[2] CALABRESI M, 1916, TIME 0816

[3] Department of Health and Human Services, 2010, ADV COMM M NDA 21071

[4] The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study [J]. PLOS MEDICINE, 2009, 6 (09)

[5] *EUR MED AG, 2001, EPAR AV

[6] *EUR MED AG, AV PROC STEPS TAK SC

[7] Lessons from the glitazones: a story of drug development [J]. LANCET, 2001, 357 (9271) : 1870 - 1875

[8] Harris G., 2010, NY TIMES 0713

[9] Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial [J]. LANCET, 2009, 373 (9681) : 2125 - 2135

[10] Thiazolidinediones for type 2 diabetes - New agents reduce insulin resistance but need long term clinical trials [J]. BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7256): : 252 - 253